Pathology of esophageal and gastric cancers Biomarkers needed in 2024
Seance of wednesday 17 april 2024 (Journée de Cancérologie : cancers oeso-gastriques)
DOI number : 10.26299/jhkk-ez97/emem.2024.14.01
Abstract
Esophageal and gastric cancers are particularly heterogeneous. Pathology plays an important role in the management of these cancers: diagnostic role through examination of biopsy samples and surgical specimens, prognostic role and even predictive role of response to treatment through molecular analysis. New treatments are being proposed, which has considerably increased the need for biomarker research on these cancers.
This presentation will focus on the morphological diagnostic approach to adenocarcinoma (diagnostic pitfalls, histological subtypes, intra-tumoral heterogeneity), the major role of molecular biomarkers (HER2, PD-L1, dMMR/MSI) and the specificities of diagnosis in a hereditary context. The objectives of this session are:
1. Illustrate the different histological classifications and their correspondence;
2. explain the issues involved in defining diffuse cancers / poorly cohesive cell carcinomas;
3. detail the biomarkers that will be essential in 2024, and the methods for assessing them.
This presentation will focus on the morphological diagnostic approach to adenocarcinoma (diagnostic pitfalls, histological subtypes, intra-tumoral heterogeneity), the major role of molecular biomarkers (HER2, PD-L1, dMMR/MSI) and the specificities of diagnosis in a hereditary context. The objectives of this session are:
1. Illustrate the different histological classifications and their correspondence;
2. explain the issues involved in defining diffuse cancers / poorly cohesive cell carcinomas;
3. detail the biomarkers that will be essential in 2024, and the methods for assessing them.